Company news
Chimeric Therapeutics Limited news in 2022
Chimeric Therapeutics Limited's news releases, calls and decks from 2022, newest first.
Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial
December 21, 2022
Exclusive license agreement with CWRU for CORE-NK platform
November 20, 2022
Patent received in Japan for CLTX CAR technology
August 2, 2022
Licenses viral vector technology from Penn for CDH17
June 28, 2022
A$30 million Equity Placement Agreement with L1 Capital
June 9, 2022
Strategic manufacturing partnership with WuXi ATU
April 12, 2022
Security Class Reinstatement to Quotation CHMO
March 27, 2022
CDH17 car t preclinical data featured in nature cancer
March 23, 2022
Completion of retail component of Entitlement Offer
March 22, 2022
Security Class Suspension from Quotation CHMO
March 20, 2022
Final Results in Phase 1 Trial of CORE NK Platform
March 6, 2022
Chimeric partners with be the match biotherapies
March 4, 2022
Successful completion of Institutional Entitlement Offer
February 22, 2022
Entitlement Offer to raise approximately $18.1 million
February 21, 2022
Encouraging data from 2nd dose cohort in CLTX CAR T trial
February 7, 2022
Sponsored Research Agreement with University of Pennsylvania
January 31, 2022
Chimeric receives US patent covering CLTX CAR technology
January 26, 2022
Decks in 2022
- Shareholder Meeting (November 2022)
Shareholder meeting · 24 slides · Nov 15, 2022
- Technical Presentation (March 2022)
Technical · 16 slides · Mar 7, 2022
- Investor Presentation (February 2022)
Investor deck · 44 slides · Feb 22, 2022